Mellinger Jessica L, Winder Gerald Scott, Fernandez Anne C, Asefah Haila, Zikmund-Fisher Brian J
Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, United States of America; Department of Psychiatry, Michigan Medicine, Ann Arbor, MI, United States of America.
Department of Psychiatry, Michigan Medicine, Ann Arbor, MI, United States of America; University of Michigan Department of Surgery, Michigan Medicine, Ann Arbor, MI, United States of America; University of Michigan Department of Neurology, Michigan Medicine, Ann Arbor, MI, United States of America.
J Subst Use Addict Treat. 2024 Jun;161:209292. doi: 10.1016/j.josat.2024.209292. Epub 2024 Feb 14.
Despite the mortality benefits of alcohol cessation and alcohol treatment, few patients with alcohol-related liver disease (ALD) get such treatment. To understand reasons for low treatment rates, we performed a qualitative mental models study to explore how ALD patients understand factors influencing alcohol cessation, relapse and their liver health.
Using a mental models framework, we interviewed experts in alcohol use disorder (AUD) and ALD to determine factors influencing alcohol cessation, risk of relapse and liver health. An expert influence diagram was constructed and used to develop a patient interview guide. We recruited participants with ALD enrolled in hepatology or transplant clinics at a single tertiary-care center. We conducted interviews either face-to-face or by phone, per participant preference. We transcribed all interviews verbatim and analyzed them using combined deductive coding schema based on both the interview guide and emergent coding.
25 (10 women, 15 men) participants with a mean age of 57 years completed interviews. 68 % had decompensated cirrhosis. Major omissions included gender (as a factor in alcohol use or liver disease) and the influence of benzodiazepines/opioids on relapse. Misconceptions were common, in particular the idea that the absence of urges to drink meant participants were safe from relapse. Conceptual differences from the expert model emerged as well. Participants tended to view the self as primary and the only thing that could influence relapse in many cases, resulting in a linear mental model with few nodes influencing alcohol cessation. Participants' risky drinking signals (i.e., elevated liver enzymes) differed from known definitions of hazardous or high-risk drinking, which largely emphasize dose of alcohol consumed irrespective of consequences. Finally, participants sometimes viewed stopping on one's own as the primary means of stopping alcohol use, not recognizing the many other nodes in the influence diagram impacting ability to stop alcohol.
Patients with ALD had critical misconceptions, omissions, and conceptual reorganizations in their mental models of the ability to stop alcohol use. Attention to these differences may allow clinicians and researchers to craft more impactful interventions to improve rates of alcohol abstinence and AUD treatment engagement.
尽管戒酒和酒精治疗对降低死亡率有益,但很少有酒精性肝病(ALD)患者接受此类治疗。为了解治疗率低的原因,我们开展了一项定性心智模型研究,以探讨ALD患者如何理解影响戒酒、复发及其肝脏健康的因素。
我们使用心智模型框架,采访了酒精使用障碍(AUD)和ALD领域的专家,以确定影响戒酒、复发风险和肝脏健康的因素。构建了一个专家影响图,并用于制定患者访谈指南。我们在一家三级医疗中心招募了肝病科或移植诊所的ALD患者。根据参与者的偏好,我们通过面对面或电话方式进行访谈。我们逐字转录了所有访谈内容,并使用基于访谈指南和新出现编码的组合演绎编码模式对其进行分析。
25名(10名女性,15名男性)平均年龄为57岁的参与者完成了访谈。68%的人患有失代偿期肝硬化。主要遗漏包括性别(作为酒精使用或肝病的一个因素)以及苯二氮卓类药物/阿片类药物对复发的影响。误解很常见,特别是认为没有饮酒冲动意味着参与者不会复发。与专家模型的概念差异也出现了。参与者倾向于将自我视为主要因素,并且在许多情况下认为自我是唯一能够影响复发的因素,从而形成了一个线性心智模型,几乎没有节点影响戒酒。参与者的危险饮酒信号(即肝酶升高)与已知的有害或高风险饮酒定义不同,后者主要强调饮酒量而不考虑后果。最后,参与者有时将自行戒酒视为戒酒的主要方式,没有认识到影响图中许多其他节点对戒酒能力的影响。
ALD患者在戒酒能力的心智模型中存在关键的误解、遗漏和概念重组。关注这些差异可能使临床医生和研究人员制定更有效的干预措施,以提高戒酒率和AUD治疗参与度。